Eszter Lazar-Molnar

Eszter Lazar-Molnar, PhD, D(ABMLI), F(ACHI)

Languages spoken: Hungarian, English

  • Dr. Lazar-Molnar is an Associate Professor in the Department of Pathology at the University of Utah School of Medicine. She is the director of the Histocompatibility and Immunogenetics laboratory at University of Utah Health, and medical director in the Immunology division at ARUP Laboratories.

    She is board certified by the American Board of Medical Laboratory Immunology (ABMLI), and is a Fellow of the American College of Histocompatibility and Immunogenetics (ACHI).

    Dr. Lazar-Molnar’s primary interest is diagnostic laboratory immunology, including transplantation testing for pre- and post-transplant monitoring, HLA-disease, and HLA-pharmacogenetic associations, and test interference by monoclonal antibody therapeutics.

    Specialties

    • Clinical and Diagnostic Immunology

    Board Certification

    American Board of Histocompatibility & Immunogenetics
    American Board of Medical Laboratory Immunology

  • Dr. Lazar-Molnar is an Associate Professor in the Department of Pathology at the University of Utah School of Medicine. She is the director of the Histocompatibility and Immunogenetics laboratory at University of Utah Health, and medical director in the Immunology division at ARUP Laboratories.

    She is board certified by the American Board of Medical Laboratory Immunology (ABMLI), and is a Fellow of the American College of Histocompatibility and Immunogenetics (ACHI).

    Dr. Lazar-Molnar’s primary interest is diagnostic laboratory immunology, including transplantation testing for pre- and post-transplant monitoring, HLA-disease, and HLA-pharmacogenetic associations, and test interference by monoclonal antibody therapeutics.

    Board Certification and Academic Information

    Academic Departments Pathology -Primary
    Board Certification
    American Board of Histocompatibility & Immunogenetics
    American Board of Medical Laboratory Immunology

    Education history

    Fellowship Immunology - University of Utah Clinical Fellow
    Microbiology & Immunology - Albert Einstein College of Medicine Postdoctoral Fellow
    Doctoral Training Genetics, Cell and Immunobiology - Semmelweis University School of Medicine Ph.D.
    Pharmacy - University of Medicine and Pharmacy of Târgu Mureș Pharm.D.

    Selected Publications

    Journal Article

    1. Pavlov IY, Cucnik S, Delgado JC, Lazar-Molnar E (In Preparation). Expanding the clinical utility of reporter gene assay to infliximab biosimilars. (Epub ahead of print) Clin Chim Acta.
    2. Jain D, Pido MTJ, Delgado JC, Willrich MAV, Lazar-Molnar E (In Press). Comparison of Two Clinical Laboratory Assays for Measuring Serum Adalimumab and Antibodies to Adalimumab. (Epub ahead of print) The Journal of Applied Laboratory Medicine.
    3. Potter S, Sudarshan D, Lzr-Molnr E, Baker S, Metcalf RA, Lin L (2022). Life threatening platelet transfusion refractoriness due to an anamnestic human leukocyte antigen alloantibody response. Transfusion, 62(11), 2161-2162. (Read full article)
    4. Profaizer T, Dibb K, Bethers H, Monds C, Andreasen J, Delgado JC, Lzr-Molnr E (2021). Comparison of Next-Generation Sequencing-Based Human Leukocyte Antigen Typing with Clinical Flow Cytometry and Allele-Specific PCR Melting Assays for HLA-B27 Genotyping. J Appl Lab Med, 6(5), 1221-1227. (Read full article)
    5. Luo YR, Chakraborty I, Lazar-Molnar E, Wu AHB, Lynch KL (2020). Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies. Clin Chem, 66(10), 1319-1328. (Read full article)
    6. Profaizer T, Pole A, Monds C, Delgado JC, Lzr-Molnr E (2020). Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing. Hum Immunol, 81(7), 354-360. (Read full article)
    7. Ravkov EV, Charlton CM, Barker AP, Hill H, Peterson LK, Slev P, Tebo A, Voelkerding KV, Wittwer CT, Heikal N, Delgado JC, Lzr-Molnr E, Kumnovics A (2019). Evaluation of Mass Cytometry in the Clinical Laboratory. Cytometry B Clin Cytom, 96(4), 266-274. (Read full article)
    8. Pavlov IY, Parker RL, Lzr-Molnr E, Strathmann FG, Delgado JC (2019). Inductively coupled plasma mass spectrometry assay for quantification of free infliximab in serum. J Immunol Methods, 470, 33-39. (Read full article)
    9. Yang Y, Wysocki E, Antwi K, Niederkofler E, Leung EKY, Lazar-Molnar E, Yeo KJ (2018). Development and validation of a targeted affinity-enrichment and LC-MS/MS proteomics approach for the therapeutic monitoring of adalimumab. Clin Chim Acta, 483, 308-314. (Read full article)
    10. Willrich MAV, Lazar-Molnar E, Snyder MR, Delgado JC (2018). Comparison of clinical laboratory assays for measuring serum infliximab and antibodies for infliximab. J Appl Lab Med, 2(6), 893-903.
    11. Profaizer T, Lzr-Molnr E, Pole A, Delgado JC, Kumnovics A (2017). HLA genotyping using the Illumina HLA TruSight next-generation sequencing kits: A comparison. Int J Immunogenet, 44(4), 164-168. (Read full article)
    12. Lzr-Molnr E, Scandiuzzi L, Basu I, Quinn T, Sylvestre E, Palmieri E, Ramagopal UA, Nathenson SG, Guha C, Almo SC (2017). Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine, 17, 30-44. (Read full article)
    13. Lzr-Molnr E, Delgado JC (2016). Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory. Clin Chem, 62(9), 1186-98. (Read full article)
    14. Profaizer T, Lzr-Molnr E, Close DW, Delgado JC, Kumnovics A (2016). HLA genotyping in the clinical laboratory: comparison of next-generation sequencing methods. HLA, 88(1-2), 14-24. (Read full article)
    15. Pavlov IY, Carper J, Lzr-Molnr E, Delgado JC (2016). Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab. Clin Chim Acta, 453, 147-53. (Read full article)
    16. Lazar-Molnar E, Tebo AE (2014). Autoimmune NMDA receptor encephalitis. Clin Chim Acta, 438, 90-7. (Read full article)
    17. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015). Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med, 21(1), 24-33. (Read full article)
    18. Scandiuzzi L, Ghosh K, Hofmeyer KA, Abadi YM, Lzr-Molnr E, Lin EY, Liu Q, Jeon H, Almo SC, Chen L, Nathenson SG, Zang X (2014). Tissue-expressed B7-H1 critically controls intestinal inflammation. Cell Rep, 6(4), 625-32. (Read full article)
    19. Arora P, Baena A, Yu KO, Saini NK, Kharkwal SS, Goldberg MF, Kunnath-Velayudhan S, Carreo LJ, Venkataswamy MM, Kim J, Lazar-Molnar E, Lauvau G, Chang YT, Liu Z, Bittman R, Al-Shamkhani A, Cox LR, Jervis PJ, Veerapen N, Besra GS, Porcelli SA (2014). A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity, 40(1), 105-16. (Read full article)
    20. Vigdorovich V, Ramagopal UA, Lzr-Molnr E, Sylvestre E, Lee JS, Hofmeyer KA, Zang X, Nathenson SG, Almo SC (2013). Structure and T cell inhibition properties of B7 family member, B7-H3. Structure, 21(5), 707-17. (Read full article)
    21. Lzr-Molnr E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, Porcelli SA, Almo SC, Nathenson SG, Jacobs WR Jr (2010). Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A, 107(30), 13402-7. (Read full article)
    22. Chattopadhyay K, Lazar-Molnar E, Yan Q, Rubinstein R, Zhan C, Vigdorovich V, Ramagopal UA, Bonanno J, Nathenson SG, Almo SC (2009). Sequence, structure, function, immunity: structural genomics of costimulation. Immunol Rev, 229(1), 356-86. (Read full article)
    23. Lzr-Molnr E, Yan Q, Cao E, Ramagopal U, Nathenson SG, Almo SC (2008). Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A, 105(30), 10483-8. (Read full article)
    24. Shi L, Albuquerque PC, Lazar-Molnar E, Wang X, Santambrogio L, Gcser A, Nosanchuk JD (2008). A monoclonal antibody to Histoplasma capsulatum alters the intracellular fate of the fungus in murine macrophages. Eukaryot Cell, 7(7), 1109-17. (Read full article)
    25. Lzr-Molnr E, Gcser A, Freeman GJ, Almo SC, Nathenson SG, Nosanchuk JD (2008). The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. Proc Natl Acad Sci U S A, 105(7), 2658-63. (Read full article)
    26. Lazar-Molnar E, Almo SC, Nathenson SG (2006). The interchain disulfide linkage is not a prerequisite but enhances CD28 costimulatory function. Cell Immunol, 244(2), 125-9. (Read full article)
    27. Lzr-Molnr E, Hegyesi H, Pllinger E, Kovcs P, Tth S, Fitzsimons C, Cricco G, Martin G, Bergoc R, Darvas Z, Rivera ES, Falus A (2002). Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6. Eur J Clin Invest, 32(10), 743-9. (Read full article)
    28. Szincsk N, Hegyesi H, Hunyadi J, Martin G, Lzr-Molnr E, Kovcs P, Rivera E, Falus A, Juhsz I (2002). Cimetidine and a tamoxifen derivate reduce tumour formation in SCID mice xenotransplanted with a human melanoma cell line. Melanoma Res, 12(3), 231-40. (Read full article)
    29. Lzr-Molnr E, Hegyesi H, Tth S, Falus A (2000). Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine, 12(6), 547-54. (Read full article)

    Review

    1. T Profaizer, E Lazar-Molnar (2022). Quantifying Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients. ASHI Quarterly, 2022, Volume 46, Number 2. [Review]. ASHI Quarterly, 46(2).
    2. T Profaizer, E Lazar-Molnar (2020). Cell-Free DNA and its Applications in Laboratory Medicine. ASHI Quarterly, 2020, Volume 44, Number 2, pg22. [Review]. ASHI Quarterly, 44(2), 22.
    3. Lzr-Molnr E, Delgado JC (2019). Implications of Monoclonal Antibody Therapeutics Use for Clinical Laboratory Testing. [Review]. Clin Chem, 65(3), 393-405.
    4. Lazar-Molnar E, Snyder M (2018). The Role of Human Leukocyte Antigen in Celiac Disease Diagnostics. [Review]. Clin Lab Med, 38(4), 655-668. (Read full article)
    5. Lazar-Molnar E, Delgado JC (2016). Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory. [Review]. Clin Chem, 62(9), 1186-98.

    Book Chapter

    1. Lazar-Molnar E, Willrich MA, Delgado JC (2023). Monoclonal Antibody Therapeutics and Immunogenicity. In Rifai, Chiu, Young, Burnham, and Wittwer (Eds.), Tietz Textbook of Laboratory Medicine (7th Edition).
    2. Kumnovics A, Lazar-Molnar E, Delgado JC (2021). The Major Histocompatibility Complex and Disease. In McPherson RA, Pincus MR (Eds.), Henry's Clinical Diagnosis and Management by Laboratory Methods (24th). Elsevier.
    3. Lazar-Molnar E (2004). Signal-transduction pathways of histamine receptors. In Falus A (Ed.), Histamine: Biology and Medical Aspects. Budapest: SpringMed Publishing Ltd.

    Other

    1. Falus A, Hegyesi H, Lzr-Molnr E, Ps Z, Lszl V, Darvas Z (2001). Paracrine and autocrine interactions in melanoma: histamine is a relevant player in local regulation. Trends Immunol (22(12), pp. 648-52). England. (Read full article)

    Patent

    1. Lazar-Molnar E, Almo SC (2014). A Selective High-Affinity Immune Stimulatory Reagent And Uses Thereof, International Patent No. PCT/US2014/15235. U.S. Patent No. WO 2014124217 A1. Washington, D.C.:U.S. Patent and Trademark Office.

  • News & Podcasts